WANY
FENC icon

Wealthspire Advisors (New York)’s Fennec Pharmaceuticals FENC Stock Holding History

Wealthspire Advisors (New York)’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,000
Closed -$202K – 590
2022
Q3 		$202K Hold
25,000
– – ﹤0.01% 477
2022
Q2 		$141K Hold
25,000
– – ﹤0.01% 480
2022
Q1 		$140K Hold
25,000
– – ﹤0.01% 419
2021
Q4 		$110K Buy
+25,000
New +$186K ﹤0.01% 525

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Wealthspire Advisors (New York)'s FENC Position: Q4 2022 in Review

Wealthspire Advisors (New York) sold out of Fennec Pharmaceuticals (FENC) in Q4 2022, closing a stake of 25,000 shares — an estimated $202K sold.

Wealthspire Advisors (New York) first reported a position in FENC in Q4 2021 and held it in 4 quarters. The position peaked at $202K in Q3 2022. 43 funds tracked by Wall St. Rank hold FENC as of Q4 2022.

  • Wealthspire Advisors (New York) reported no remaining Fennec Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 25,000 Fennec Pharmaceuticals shares in Q4 2022, an estimated $202K.
  • Wealthspire Advisors (New York) first reported a position in Fennec Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Wealthspire Advisors (New York)'s Fennec Pharmaceuticals position peaked at $202K in Q3 2022.
  • 43 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q4 2022.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2022, filed 14 Feb 2023.